Miss Debbie Rai
- Affiliate -Clinical Trials Unit (School of Cancer Sciences)
email:
Debbie.Rai@glasgow.ac.uk
Coap, Alexander Stone Building, Alexander Stone Building
The University of Glasgow uses cookies for analytics. Find out more about our Privacy policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and can only be disabled by changing your browser preferences.
Analytical cookies help us improve our website. We use Google Analytics. All data is anonymised.
Hotjar and Clarity help us to understand our users’ behaviour by visually representing their clicks, taps and scrolling. All data is anonymised.
email:
Debbie.Rai@glasgow.ac.uk
Coap, Alexander Stone Building, Alexander Stone Building
Banerjee, S. et al. (2023) Efficacy and safety of weekly paclitaxel plus vistusertib vs paclitaxel alone in patients with platinum-resistant ovarian high-grade serous carcinoma: the OCTOPUS multicenter, phase 2, randomized clinical trial. JAMA Oncology, 9(5), pp. 675-682. (doi: 10.1001/jamaoncol.2022.7966) (PMID:36928279) (PMCID:PMC10020933)
Zhou, C. et al. (2019) Dynamics of circulating vascular endothelial growth factor-A predict benefit from antiangiogenic cediranib in metastatic or recurrent cervical cancer patients. British Journal of Clinical Pharmacology, 85(8), pp. 1781-1789. (doi: 10.1111/bcp.13965) (PMID:30980733) (PMCID:PMC6624436)
Symonds, R. P. et al. (2015) Cediranib combined with carboplatin and paclitaxel in patients with metastatic or recurrent cervical cancer (CIRCCa): a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Oncology, 16(15), pp. 1515-1524. (doi: 10.1016/S1470-2045(15)00220-X) (PMID:26474517) (PMCID:PMC4705431)
Banerjee, S. et al. (2023) Efficacy and safety of weekly paclitaxel plus vistusertib vs paclitaxel alone in patients with platinum-resistant ovarian high-grade serous carcinoma: the OCTOPUS multicenter, phase 2, randomized clinical trial. JAMA Oncology, 9(5), pp. 675-682. (doi: 10.1001/jamaoncol.2022.7966) (PMID:36928279) (PMCID:PMC10020933)
Zhou, C. et al. (2019) Dynamics of circulating vascular endothelial growth factor-A predict benefit from antiangiogenic cediranib in metastatic or recurrent cervical cancer patients. British Journal of Clinical Pharmacology, 85(8), pp. 1781-1789. (doi: 10.1111/bcp.13965) (PMID:30980733) (PMCID:PMC6624436)
Symonds, R. P. et al. (2015) Cediranib combined with carboplatin and paclitaxel in patients with metastatic or recurrent cervical cancer (CIRCCa): a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Oncology, 16(15), pp. 1515-1524. (doi: 10.1016/S1470-2045(15)00220-X) (PMID:26474517) (PMCID:PMC4705431)